HCW Biologics Inc. - 8-K Filing
HCW Biologics Inc. entered into a Securities Purchase Agreement on May 21, 2026, with accredited investors for the sale of approximately $4 million in gross proceeds through the issuance of units consisting of common stock and warrants. The company plans to use funds for clinical trials, IND-enabling studies, corporate purposes, and debt settlements. (Items: 1.01 Entry into a Material Definitive Agreement, 3.02 Unregistered Sales of Equity Securities, 7.01 Regulation FD Disclosure, 8.01 Other Events)
Tickers: $HCWB